India Bio-Pharmaceuticals Industry Expected to Generate a Value of INR 2891.70 Billion Between 2018-2023 -

DUBLIN--()--The "Bio-Pharmaceuticals Industry In India (2018-2023) with data Biotechnology Market and Pharmaceutical Company Information" report has been added to's offering.

The bio-pharmaceuticals market in India is expected to reach a value of INR 2,891.70 Bn in FY 2023, expanding at a compound annual growth rate (CAGR) of ~31.7% since FY 2018.

Market insights

India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications. Currently, bio-pharmaceuticals is one of the fastest growing biotechnology segments in India. The significant bio-pharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.

Government initiatives and investments:

The major investors in the Indian bio-pharmaceutical market are AstraZeneca, Johnson & Johnson, GlaxoSmithKline (GSK), Nipro and Otsuka. In 2017, 46 mergers and acquisition (M&A) deals were signed in the Indian bio-pharmaceutical market, generating business worth INR 94.77 Bn. The Indian government has taken the initiative to set up an electronic platform for regulating online pharmacies. Pharma Vision 2020' has been unveiled so that India can emerge as a global leader in terms of end-to-end drug manufacturing.

Key growth drivers of the market:

India comprises of ~0.13 Mn highly skilled and experienced scientists who serve as a strong support system for the business process of the bio-pharmaceutical industry. With the help of the educational qualifications and skillset of these people, India is considered to be a significant center for bio-pharmaceutical research and development (R&D), especially for vaccine manufacturing.

The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India (i3) program, for collaboration of industrial organizations and academic organizations over the next five years. This program is considered to act as a significant action of the Government in its way of boosting bio-pharmaceutical production in the country.

Key deterrents to the growth of the market:

It often takes a long time for the manufacturing companies to launch a new market-ready bio-pharmaceutical product in India due to the existence of numerous regulatory challenges in the process.

Also, the Indian bio-pharmaceutical industry lacks proper infrastructure regarding limited government-sponsored laboratory space, consumables, chemical components, and equipment, which acts as a significant hindrance to the growth of the market.

Key Topics Covered:

1. Executive summary

2. Socio-economic indicators

3. Introduction

3.1. Bio-pharmaceuticals market definition and structure

3.2. Bio-pharmaceuticals value chain

4. Global pharmaceuticals market

4.1. Market overview

4.2. Market segmentation

4.2.1. Pharmaceuticals market value - country-wise split (2017)

  • USA
  • Japan
  • China
  • Germany
  • France
  • Others

4.2.2. Pharmaceutical spending - region-wise split (2020e)

  • USA
  • EU-5
  • Others

4.2.3. Pharmaceuticals market players - ranking (2017)

4.3. Bio-pharmaceuticals sales growth (2007-2017)

5. India bio-pharmaceuticals market

5.1. Market overview

5.2. Market size and growth forecast - value-wise (FY 2016-FY 2023e)

5.3. Market segmentation

5.3.1. Revenue-wise market breakup (FY 2016)

5.3.2. Top five pharmaceutical company market share (2018)

  • Cipla
  • Aurobindo Pharma
  • Lupin
  • Others

5.4. Recent investments in the market

5.5. Government initiatives

5.6. Biotechnology and pharmaceutical research and development (R&D) hubs in India - overview

5.7. Porter's five forces analysis

6. Trade analysis

6.1. Export of bio-pharmaceuticals

  • Value-wise
  • Volume-wise
  • Country-wise

6.2. Import of bio-pharmaceuticals

7. Key growth drivers of the market

8. Key deterrents to the growth of the market

9. Competitive landscape

9.1. Biocon Ltd.

  • Corporate information
  • Business description
  • Products and services
  • Key people
  • Financial snapshot (total income, net profit/loss)
  • Key ratios
  • Annual research & development spends
  • Business segments, geographic segments
  • Production capacities

9.2. Cadila Healthcare Ltd.

9.3. Dr Reddy's Laboratories Ltd.

9.4. Panacea Biotec Ltd.

9.5. Wockhardt Ltd.

9.6. GSK Pharmaceuticals Ltd.

9.7. Bharat Biotech International Ltd.

9.8. Bharat Serums and Vaccines Ltd.

9.9. Indian Immunologicals Ltd.

9.10. Serum Institute of India Pvt. Ltd.10. Recent developments

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900